Q-omics provides the consensus-scored FTH1P22 profile across patient tissues and cancer cell-line models. FTH1P22 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, FTH1P22 is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, FTH1P22 RNA expression shows 16,176 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, KIRC, and LSCC as cancer lineages where FTH1P22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FTH1P22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FTH1P22 survival associations across molecular data types. FTH1P22 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FTH1P22 RNA expression–survival associations across cancer types. High FTH1P22 expression shows unfavorable associations in LGG, but favorable associations in SKCM, HNSC, CESC, UCS and BRCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for FTH1P22 RNA expression.
This table summarizes FTH1P22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FTH1P22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FTH1P22 shows lower tumor expression in THCA, LUSC and LIHC and higher tumor expression in KIRC and STAD. The KIRC box plot shows higher FTH1P22 RNA expression in tumor versus normal tissue (log2 FC = +1.765, t-test p < 0.001).
This table shows molecular features associated with FTH1P22 in patient tissues and cancer cell lines. In patient samples, FTH1P22 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
